NovoCure Limited (NASDAQ:NVCR – Get Free Report) has been assigned an average rating of “Hold” from the eight research firms that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $22.33.
Several equities analysts have recently issued reports on the company. Wedbush reduced their price objective on NovoCure from $20.00 to $19.00 and set a “neutral” rating for the company in a research report on Tuesday, November 10th. HC Wainwright set a $32.00 price target on NovoCure in a research report on Friday, July 24th. Wells Fargo & Company decreased their price target on NovoCure from $20.00 to $15.00 and set an “equal weight” rating for the company in a research note on Friday, October 30th. Weiss Ratings cut NovoCure from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, October 30th. Finally, Ladenburg Thalmann & Co. Inc. raised their price target on NovoCure from $27.00 to $31.00 and gave the company a “buy” rating in a report on Tuesday, November 10th.
View Our Latest Research Report on NVCR
Hedge Funds Weigh In On NovoCure
NovoCure Stock Down 1.4%
Shares of NASDAQ:NVCR opened at $11.14 on Wednesday. The company’s 50-day moving average price is $14.59 and its 200 day moving average price is $14.74. NovoCure has a fifty-two week low of $9.82 and a fifty-two week high of $21.45. The company has a current ratio of 2.49, a quick ratio of 2.34 and a debt-to-equity ratio of 0.49.
NovoCure (NASDAQ:NVCR – Get Free Report) last posted its earnings results on Thursday, October 29th. The medical equipment provider reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.14. NovoCure had a negative net margin of 16.78% and a negative return on equity of 35.81%. The firm had revenue of $193.40 million during the quarter, compared to analyst estimates of $182.28 million. During the same period in the previous year, the business posted ($0.33) EPS. NovoCure’s revenue was up 15.7% on a year-over-year basis. On average, research analysts predict that NovoCure will post -1.10 earnings per share for the current fiscal year.
NovoCure Company Profile
NovoCure is a global oncology company that develops and commercializes Tumor Treating Fields (TTFields), a cancer treatment that uses wearable devices to deliver low-intensity electric fields intended to disrupt cancer cell division. Its products include Optune Gio and Optune Lua, which are used to treat certain cancers. The company is headquartered in Baar, Switzerland, and serves patients in markets across North America, Europe and Asia. NovoCure was founded in 2000 by Yoram Palti, a medical researcher who developed the TTFields approach.
Featured Stories
- Five stocks we like better than NovoCure
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for NovoCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovoCure and related companies with MarketBeat.com's FREE daily email newsletter.
